WO2000034503A2 - Methods of producing esters of mycophenolate - Google Patents

Methods of producing esters of mycophenolate Download PDF

Info

Publication number
WO2000034503A2
WO2000034503A2 PCT/IN1999/000070 IN9900070W WO0034503A2 WO 2000034503 A2 WO2000034503 A2 WO 2000034503A2 IN 9900070 W IN9900070 W IN 9900070W WO 0034503 A2 WO0034503 A2 WO 0034503A2
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
added
organic solvent
hrs
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN1999/000070
Other languages
French (fr)
Other versions
WO2000034503A3 (en
Inventor
Anindya Sircar
Anand Khedkar
Madhav Kulkarni
Shrikumar Suryanarayan
Madhavan Sridharan
Poorpanapranja Acharaya
Ganesh Samvasivam
Ramakrishnan Melarkode
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon India Ltd filed Critical Biocon India Ltd
Priority to AT99964770T priority Critical patent/ATE307892T1/en
Priority to US09/857,579 priority patent/US6709846B1/en
Priority to EP99964770A priority patent/EP1137795B1/en
Priority to CA2354554A priority patent/CA2354554C/en
Priority to AU30732/00A priority patent/AU3073200A/en
Priority to DE69928002T priority patent/DE69928002T2/en
Publication of WO2000034503A2 publication Critical patent/WO2000034503A2/en
Publication of WO2000034503A3 publication Critical patent/WO2000034503A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid

Definitions

  • This invention relates to an improved process for the manufacture of Mycophenolate Mofetil by a biochemical method using enzymes or chemically without the use of any catalyst
  • Mycophenolate mofetil of formula I is the morpholinoethyl ester of Mycophenolic acid (MPA).
  • Mycophenolate mofetil is an immunosuppressant. It is derived from mycophenolic acid which was isolated from a fungus and chemically modified to improve oral absorption. Mycophenolate mofetil, the pharmaceutically acceptable salt thereof is used as an immunosuppressive agent, anti- inflammatory, anti-tumor and anti-viral agent.
  • the present invention concerns methods for making Mycophenolate mofetil by :
  • This invention relates to a process for the conversion of Mycophenolic acid and 2-morpholino ethanol into Mycophenolate Mofetil.
  • the substrates, MPA and 2- morpholino ethanol are added in an organic solvent or a mixture of more than one organic solvents , water is added to the system to adjust the water content and pH in the microenvironment, enzyme is added to this system, the mixture is incubated at a temperature between 20 to 55 deg C, the reaction is carried out for a time upto 120 hr, the esterif ⁇ ed product is analyzed by HPLC method.
  • the MPA is used in a concentration range of 0.03 to 5%.
  • the 2-morpholino ethanol is used in molar equivalent of 1 to 15 with respect to MPA.
  • the MPA and 2-morpholino ethanol are added to the organic solvent or mixture of organic solvents more than one, where the organic solvent is a C6-C12 alkane such as iso-octane, n-hexane, cyclohexane, heptane, octane or a C2-C12 alcohol such as ethanol, propanol, 2-propanol, hexanol, octanol, or isopropanol.
  • the organic solvent is a C6-C12 alkane such as iso-octane, n-hexane, cyclohexane, heptane, octane or a C2-C12 alcohol such as ethanol, propanol, 2-propanol, hex
  • a surfactant is added to the organic solvent or in the mixture of the organic solvents which is Sodium bis (ethylhexyl) sulfosuccinate (Aerosol OT or AOT), Cetyl trimethyl ammonium bromide or Trimethyl octyl ammonium chloride (TOMAC).
  • the water content (Wo) which is the molar ratio of the water to the surfactant, is adjusted to a value in the range of 1 to 30.
  • the pH of the microenvironment is adjusted in a range of 3 to 8 using buffer such as acetate or phosphate buffer.
  • the enzyme which is used for the bioconversion is a hydrolase which may be lipase, cutinase, esterase or a protease from microbial, animal or plant origin.
  • the enzyme is added in organic solvent in absence or presence of a surfactant.
  • the reaction is carried out at a temperature in a range of 20 to 55 deg C.
  • the time period of reaction is upto 120 hrs.
  • the esterified product is analyzed by HPLC method.
  • Another method for producing mycophenolate mofetil comprises heating and or refluxing MPA (mycophenolic acid) with a large excess of 2-morpholino ethanol in the absence of any other organic solvent or catalyst.
  • the MPA is heated and optionally refluxed with a large excess of 2-morpholino ethanol at a temperature between 80 to 150 deg C.
  • the reaction is carried out for a time period of 12 to 120 hrs.
  • a 50 mM solution of AOT in 10 ml isooctane was prepared.
  • MPA in a concentration of 0.6 mM
  • 2-morpholino ethanol 0.9 mM were added.
  • acetate buffer (pH 5.0) was added to adjust the Wo to 3.0.
  • Lipase from Candida rugosa was added in a concentration of 1 mg/ml.
  • the reaction mixture was incubated at a temperature of 37 deg C for 24 hrs.
  • the esterified product was analyzed by HPLC.
  • Example 2 A 100 mM solution of AOT in 10 ml isooctane was prepared. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. To this mixture acetate buffer (pH 4.5) was added to adjust the Wo to 2.8. Lipase from Mucor meihei was added in a concentration of 10 mg/ml. The reaction mixture was incubated at a temperature of 37 deg C for 48 hrs. The esterified product was analyzed by HPLC.
  • Example 3 A 100 mM solution of AOT in 10 ml isooctane was prepared. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. To this mixture acetate buffer (pH 4.5) was added to adjust the Wo to 2.8. Lipase from Mucor meihei was added in a concentration of 10 mg/ml. The reaction mixture was incubated
  • a 100 mM solution of AOT in 50 ml isooctane was prepared.
  • MPA in a concentration of 0.6 mM
  • 2-morpholino ethanol 9.0 mM were added.
  • acetate buffer (pH 4.5) was added to adjust the Wo to 10.
  • Lipase from Candida albicans was added in a concentration of 7 mg/ml.
  • the reaction mixture was incubated at a temperature of 37 deg C for 48 hrs.
  • the esterified product was analyzed by HPLC.
  • a 100 mM solution of CTAB in 50 ml isooctane with ethanol as a cosolvent was prepared.
  • MPA in a concentration of 0.6 mM
  • 2-morpholino ethanol 9.0 mM were added.
  • phosphate buffer (pH 7.0) was added to adjust the Wo to 20.
  • Pig liver esterase was added in a concentration of 5 mg/ml.
  • the reaction mixture was incubated at a temperature of 37 deg C for 96 hrs.
  • the esterified product was analyzed by HPLC.
  • Example 5 A 100 mM solution of TOMAC in 50 ml octanol with propanol as a cosolvent was prepared.
  • MPA in a concentration of 0.6 mM
  • 2-morpholino ethanol 9.0 mM were added.
  • acetate buffer (pH 4.5) was added to adjust the Wo to 2.8.
  • Protease from serratia marcesens was added in a concentration of 7 mg/ml.
  • the reaction mixture was incubated at a temperature of 45 deg C for 120 hrs.
  • the esterified product was analyzed by HPLC.
  • a microemulsion system using hexane, water and 2 propanol in mole fraction ratio of 0.23:0.32:0.45 was prepared.
  • MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added.
  • Protease from Bacillus subtil is was added in a concentration of 7 mg/ml.
  • Cutinase was added in a concentration of 7 mg/ml.
  • the reaction mixture was incubated at a temperature of 37 deg C for 48 hrs.
  • the esterified product was analyzed by HPLC.
  • a 150 mM solution of AOT in 100 ml isooctane was added.
  • MPA in a concentration of 0.6 mM
  • 2-morpholino ethanol 9.0 mM were added.
  • acetate buffer (pH 4.5) was added to adjust the Wo to 1.5.
  • Lipase from Mucor meihei was added in a concentration of 5 mg/ml.
  • the reaction mixture was incubated at a temperature of 20 deg C for 48 hrs.
  • the esterified product was analyzed by HPLC.
  • Example 8 lOmg of MPA was taken in lOmL of 2-morpholino ethanol and the mixture was heated to 100 deg C. The temperature was maintained between 140 to 150 deg C for about 6 hrs. After the reaction was complete, lOOmL of ethyl acetate was added, the organic layers were washed with 3xl00mL of water, dried over Na 2 S0 4 and the ethyl acetate was removed under reduced pressure to afford the product.
  • Example 9 lOmg of MPA was taken in lOmL of 2-morpholino ethanol and the mixture was heated to 140 deg C under reflux. The temperature was maintained between 140 to 150 deg C for about 6 hrs.
  • Example 10 12.5 mg of MPA was taken in 20 mL of 2-morpholino ethanol and the mixture was heated to 80 deg C. The temperature was maintained between 80 to 85 deg C for about 96 hrs. After the reaction was complete, lOOmL of ethyl acetate was added, the organic layers were washed with 3xl00mL of water, dried over Na 2 S0 4 and the ethyl acetate was removed under reduced pressure to afford the product.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Methods for the manufacture of Mycophenolate are disclosed. Mycophenolate mofetil is biochemically synthesized using Mycophenolic Acid and 2-morpholino ethanol with the help of an enzyme. Mycophenolate mofetil is also chemically synthesized non-catalytically by refluxing mycophenolic acid with 2-morpholino ethanol in the absence of a third solvent or a catalyst.

Description

Methods of producing esters of Mycophenolate.
This invention relates to an improved process for the manufacture of Mycophenolate Mofetil by a biochemical method using enzymes or chemically without the use of any catalyst
BACKGROUND
Mycophenolate mofetil of formula I is the morpholinoethyl ester of Mycophenolic acid (MPA).
Formula I
Mycophenolate mofetil is an immunosuppressant. It is derived from mycophenolic acid which was isolated from a fungus and chemically modified to improve oral absorption. Mycophenolate mofetil, the pharmaceutically acceptable salt thereof is used as an immunosuppressive agent, anti- inflammatory, anti-tumor and anti-viral agent.
Chemical synthesis route for the manufacture of Mycophenolate mofetil already exists. An acid halide condensation route for the synthesizing the Mycophenolate mofetil has been described in US 4,753,935; which requires two steps and has a high dimeric impurity. Those skilled in the field of esterification reactions will appreciate that the conventional teachings for the synthesis of an ester through the reaction of an acid and an alcohol require the use of a chemical catalyst to achieve acceptable yields. The direct esterifϊcation of mycophenolic acid without any catalyst too has been disclosed in US 5,247,083, in which the reaction is carried out in the presence of an inert organic solvent.
It has surprisingly been discovered that good yields of mycophenolate mofetil can be obtained without the disadvantage of prior described methods, without the use of a third organic solvent and without the use of chemical catalysts. It has also been found that it is possible to produce mycophenolate mofetil under very mild conditions using enzymes, in the presence of water and organic solvents and no other chemical catalysts. These processes reduce the chances of unwanted side reaction and lead to purer products.
Summary of the invention.
The present invention concerns methods for making Mycophenolate mofetil by :
(i) reacting the Mycophenolic acid and a molar excess of 2-morpholino ethanol in an organic solvent along with an enzyme and an appropriate quantity of water . (ϋ) refluxing Mycophenolic acid with a large excess of 2-morpholino ethanol in the absence of any other organic solvent or a catalyst.
Detailed description of the invention.
This invention relates to a process for the conversion of Mycophenolic acid and 2-morpholino ethanol into Mycophenolate Mofetil. According to one method of this invention the substrates, MPA and 2- morpholino ethanol are added in an organic solvent or a mixture of more than one organic solvents , water is added to the system to adjust the water content and pH in the microenvironment, enzyme is added to this system, the mixture is incubated at a temperature between 20 to 55 deg C, the reaction is carried out for a time upto 120 hr, the esterifϊed product is analyzed by HPLC method.
The MPA is used in a concentration range of 0.03 to 5%. The 2-morpholino ethanol is used in molar equivalent of 1 to 15 with respect to MPA. The MPA and 2-morpholino ethanol are added to the organic solvent or mixture of organic solvents more than one, where the organic solvent is a C6-C12 alkane such as iso-octane, n-hexane, cyclohexane, heptane, octane or a C2-C12 alcohol such as ethanol, propanol, 2-propanol, hexanol, octanol, or isopropanol. A surfactant is added to the organic solvent or in the mixture of the organic solvents which is Sodium bis (ethylhexyl) sulfosuccinate (Aerosol OT or AOT), Cetyl trimethyl ammonium bromide or Trimethyl octyl ammonium chloride (TOMAC). The water content (Wo), which is the molar ratio of the water to the surfactant, is adjusted to a value in the range of 1 to 30. The pH of the microenvironment is adjusted in a range of 3 to 8 using buffer such as acetate or phosphate buffer. The enzyme, which is used for the bioconversion is a hydrolase which may be lipase, cutinase, esterase or a protease from microbial, animal or plant origin. The enzyme is added in organic solvent in absence or presence of a surfactant. The reaction is carried out at a temperature in a range of 20 to 55 deg C. The time period of reaction is upto 120 hrs. The esterified product is analyzed by HPLC method. Another method for producing mycophenolate mofetil comprises heating and or refluxing MPA (mycophenolic acid) with a large excess of 2-morpholino ethanol in the absence of any other organic solvent or catalyst. The MPA is heated and optionally refluxed with a large excess of 2-morpholino ethanol at a temperature between 80 to 150 deg C. The reaction is carried out for a time period of 12 to 120 hrs.
Both of these methods are illustrated with examples below which are not intended to be limiting.
Example 1
A 50 mM solution of AOT in 10 ml isooctane was prepared. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 0.9 mM were added. To this mixture acetate buffer (pH 5.0) was added to adjust the Wo to 3.0. Lipase from Candida rugosa was added in a concentration of 1 mg/ml. The reaction mixture was incubated at a temperature of 37 deg C for 24 hrs. The esterified product was analyzed by HPLC.
Example 2 A 100 mM solution of AOT in 10 ml isooctane was prepared. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. To this mixture acetate buffer (pH 4.5) was added to adjust the Wo to 2.8. Lipase from Mucor meihei was added in a concentration of 10 mg/ml. The reaction mixture was incubated at a temperature of 37 deg C for 48 hrs. The esterified product was analyzed by HPLC. Example 3
A 100 mM solution of AOT in 50 ml isooctane was prepared. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. To this mixture acetate buffer (pH 4.5) was added to adjust the Wo to 10. Lipase from Candida albicans was added in a concentration of 7 mg/ml. The reaction mixture was incubated at a temperature of 37 deg C for 48 hrs. The esterified product was analyzed by HPLC.
Example 4
A 100 mM solution of CTAB in 50 ml isooctane with ethanol as a cosolvent was prepared. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. To this mixture phosphate buffer (pH 7.0) was added to adjust the Wo to 20. Pig liver esterase was added in a concentration of 5 mg/ml. The reaction mixture was incubated at a temperature of 37 deg C for 96 hrs. The esterified product was analyzed by HPLC.
Example 5 A 100 mM solution of TOMAC in 50 ml octanol with propanol as a cosolvent was prepared. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. To this mixture acetate buffer (pH 4.5) was added to adjust the Wo to 2.8. Protease from serratia marcesens was added in a concentration of 7 mg/ml. The reaction mixture was incubated at a temperature of 45 deg C for 120 hrs. The esterified product was analyzed by HPLC. Example 6
A microemulsion system using hexane, water and 2 propanol in mole fraction ratio of 0.23:0.32:0.45 was prepared. In the solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. Protease from Bacillus subtil is was added in a concentration of 7 mg/ml. Cutinase was added in a concentration of 7 mg/ml. The reaction mixture was incubated at a temperature of 37 deg C for 48 hrs. The esterified product was analyzed by HPLC.
Example 7
A 150 mM solution of AOT in 100 ml isooctane was added. In the surfactant solution MPA in a concentration of 0.6 mM and 2-morpholino ethanol 9.0 mM were added. To this mixture acetate buffer (pH 4.5) was added to adjust the Wo to 1.5. Lipase from Mucor meihei was added in a concentration of 5 mg/ml. The reaction mixture was incubated at a temperature of 20 deg C for 48 hrs. The esterified product was analyzed by HPLC.
Example 8 lOmg of MPA was taken in lOmL of 2-morpholino ethanol and the mixture was heated to 100 deg C. The temperature was maintained between 140 to 150 deg C for about 6 hrs. After the reaction was complete, lOOmL of ethyl acetate was added, the organic layers were washed with 3xl00mL of water, dried over Na2S04 and the ethyl acetate was removed under reduced pressure to afford the product. Example 9 lOmg of MPA was taken in lOmL of 2-morpholino ethanol and the mixture was heated to 140 deg C under reflux. The temperature was maintained between 140 to 150 deg C for about 6 hrs. After the reaction was complete, lOOmL of ethyl acetate was added, the organic layers were washed with 3xl00mL of water, dried over Na2S04 and the ethyl acetate was removed under reduced pressure to afford the product, mycophenolate mofetil.
Example 10 12.5 mg of MPA was taken in 20 mL of 2-morpholino ethanol and the mixture was heated to 80 deg C. The temperature was maintained between 80 to 85 deg C for about 96 hrs. After the reaction was complete, lOOmL of ethyl acetate was added, the organic layers were washed with 3xl00mL of water, dried over Na2S04 and the ethyl acetate was removed under reduced pressure to afford the product.

Claims

We claim:
1. A method for the production of mycophenolate mofetil which comprises reacting mycophenolic acid and a molar excess of 2-morpholino ethanol in an organic solvent along with an enzyme and in the presence of water at a temperature between 20 -55 deg C and a pH of 3-8 for a period of upto 120 hrs.
2. The method of claim 1 where the organic solvent is a C6-C12 alkane such as iso-octane, n-hexane, cyclohexane, heptane, octane or a C2-C12 alcohol such as ethanol, propanol, iso propanol, hexanol or octanol.
3. The method of claim 2 where the organic solvent is a mixture of organic solvents .
4. The method of claim 1 where the enzyme catalyst is a hydrolase such as lipase, esterase or protease,
5. The method of claim 1 where the enzyme catalyst is a lipase or esterase.
6. The method of claims 4 and 5 where the enzyme catalyst is an immobilized enzyme .
7. The method of claims 4 and 5 where the enzyme catalyst is in a non- immobilized form.
8. The method of claim 4and 5 where the enzyme is added optionally along with a surfactant .
9. The method of claim 8 where the surfactant is Sodium 2 (ehtylhexyl) sulfosuccinate.
10. The method of claim 8 where the surfactant is Cetyl trimethylammonium bromide.
11. The method of claim 1 where the water content (Wo) is between 1-30, preferably 2-10.
12. A method for the production of mycophenolate mofetil which comprises heating mycophenolic acid with an excess of 2-morpholino ethanol in the absence of any other organic solvent or catalyst.
13. The method of the claim 11, wherein the heating is carried out at a temperature between 80 and 150 degrees.
14. The method of the claim 12 wherein the mixture is refluxed under the said conditions for a time period of 12-120 hrs.
15. The method of the claim 11 to 13, wherein the reaction is carried out for a time period of 12-120 hrs.
PCT/IN1999/000070 1998-12-09 1999-12-09 Methods of producing esters of mycophenolate Ceased WO2000034503A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT99964770T ATE307892T1 (en) 1998-12-09 1999-12-09 METHOD FOR PRODUCING MYCOPHENOLATE ESTERS
US09/857,579 US6709846B1 (en) 1998-12-09 1999-12-09 Methods of producing esters of mycophenolate
EP99964770A EP1137795B1 (en) 1998-12-09 1999-12-09 Methods of producing esters of mycophenolate
CA2354554A CA2354554C (en) 1998-12-09 1999-12-09 Methods of producing esters of mycophenolate
AU30732/00A AU3073200A (en) 1998-12-09 1999-12-09 Methods of producing esters of mycophenolate
DE69928002T DE69928002T2 (en) 1998-12-09 1999-12-09 PROCESS FOR THE PRODUCTION OF MYCOPHENOLATE ESTERS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2754/MAS/98 1998-12-09
IN2754MA1998 IN188985B (en) 1998-12-09 1998-12-09

Publications (2)

Publication Number Publication Date
WO2000034503A2 true WO2000034503A2 (en) 2000-06-15
WO2000034503A3 WO2000034503A3 (en) 2000-08-17

Family

ID=11096895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN1999/000070 Ceased WO2000034503A2 (en) 1998-12-09 1999-12-09 Methods of producing esters of mycophenolate

Country Status (10)

Country Link
US (1) US6709846B1 (en)
EP (1) EP1137795B1 (en)
AT (1) ATE307892T1 (en)
AU (1) AU3073200A (en)
CA (1) CA2354554C (en)
DE (1) DE69928002T2 (en)
DK (1) DK1137795T3 (en)
ES (1) ES2252995T3 (en)
IN (1) IN188985B (en)
WO (1) WO2000034503A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042393A1 (en) * 2001-11-16 2003-05-22 Biocon Limited Enzymatic preparation of mycophenolate mofetil
WO2005105771A1 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2005023791A3 (en) * 2003-09-11 2005-11-17 Sandoz Ag Process for the production of mycophenolate mofetil
US7019133B2 (en) * 2003-02-21 2006-03-28 Chunghwa Chemical Synthesis & Biotech Co., Ltd. Process for making mycophenolate mofetil by transesterification
JP2008511309A (en) * 2004-09-03 2008-04-17 ポリ・インドウストリア・キミカ・ソチエタ・ペル・アチオニ Preparation method of mycophenolate mofetil by enzymatic transesterification
CN100402516C (en) * 2005-10-18 2008-07-16 深圳市东阳光实业发展有限公司 A kind of preparation method of mycophenolate morphinate
DE102007061631A1 (en) 2007-02-04 2008-08-07 Formosa Laboratories, Inc. Process for the preparation of mycophenolate mofetil
US7439373B2 (en) 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CN1328272C (en) * 2005-08-22 2007-07-25 鲁南制药集团股份有限公司 Industrial production method of mycophenolic acid morpholine ester
CN100484930C (en) * 2007-03-16 2009-05-06 重庆大新药业股份有限公司 Preparation method of mycophenolate mofetil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
PL178522B1 (en) 1993-09-15 2000-05-31 Syntex Inc Crystalline anhydrous mophethyl mycophenolate and pharmaceutical agent for intravenous administration

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042393A1 (en) * 2001-11-16 2003-05-22 Biocon Limited Enzymatic preparation of mycophenolate mofetil
US7019133B2 (en) * 2003-02-21 2006-03-28 Chunghwa Chemical Synthesis & Biotech Co., Ltd. Process for making mycophenolate mofetil by transesterification
WO2005023791A3 (en) * 2003-09-11 2005-11-17 Sandoz Ag Process for the production of mycophenolate mofetil
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105771A1 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
JP2007534697A (en) * 2004-04-27 2007-11-29 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ Process for the preparation of mycophenolate mofetil and other mycophenolate esters
US7358247B2 (en) 2004-04-27 2008-04-15 TEVA Gyógyszergyár Zártköruen Muködö Részvénytársaság Mycophenolate mofetil impurity
US7439373B2 (en) 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
JP2008511309A (en) * 2004-09-03 2008-04-17 ポリ・インドウストリア・キミカ・ソチエタ・ペル・アチオニ Preparation method of mycophenolate mofetil by enzymatic transesterification
JP4880604B2 (en) * 2004-09-03 2012-02-22 ポリ・インドウストリア・キミカ・ソチエタ・ペル・アチオニ Preparation method of mycophenolate mofetil by enzymatic transesterification
CN100402516C (en) * 2005-10-18 2008-07-16 深圳市东阳光实业发展有限公司 A kind of preparation method of mycophenolate morphinate
DE102007061631A1 (en) 2007-02-04 2008-08-07 Formosa Laboratories, Inc. Process for the preparation of mycophenolate mofetil

Also Published As

Publication number Publication date
DE69928002D1 (en) 2005-12-01
AU3073200A (en) 2000-06-26
ES2252995T3 (en) 2006-05-16
CA2354554C (en) 2010-05-25
ATE307892T1 (en) 2005-11-15
US6709846B1 (en) 2004-03-23
DK1137795T3 (en) 2006-03-20
DE69928002T2 (en) 2006-07-27
IN188985B (en) 2002-11-30
CA2354554A1 (en) 2000-06-15
EP1137795B1 (en) 2005-10-26
EP1137795A2 (en) 2001-10-04
WO2000034503A3 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
EP1137795B1 (en) Methods of producing esters of mycophenolate
JPH08336393A (en) Process for producing optically active γ-substituted-β-hydroxybutyric acid ester
US6406912B1 (en) Method for enzymatic enantiomer-separation of 3(r)- and 3(s)-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridine or its carboxylic acid esters
EP0945518B1 (en) Process for producing optically active 3-quinuclidinol derivatives
US7727751B2 (en) Method for the preparation of mycophenolate mofetil by enzyme tranesterification
EP0942068B1 (en) Process for the preparation of optically active n-benzyl-3-pyrrolidinol
US6706500B2 (en) Process for the preparation of L-menthol
JP4042454B2 (en) Process for producing optically active 3-methylglutaric acid monoester
WO2003042393A1 (en) Enzymatic preparation of mycophenolate mofetil
EP1433857B1 (en) Process for producing monomer
US5011775A (en) Enzymatic process for the preparation of rosmarinic acid
Adamczyk et al. Unexpectedly facile hydrolysis of digoxin esters. The importance of appropriate controls in lipase-mediated hydrolysis
EP0745137B1 (en) Enzymatic resolution of substituted 2-methyl-propionic acid
JP4711367B2 (en) Method for producing optically active amino alcohol derivative
JPH10210997A (en) Production of optically active 3-quinacridinol
JP2003096029A (en) Optically active alcohol and method for producing the same
US7439036B2 (en) Process for producing optically active octahydro-1H-indole-2-carboxylic acid
AU645543B2 (en) Pharmaceuticals
CA2189130A1 (en) Process for producing arabino-nucleosides
JP2002017386A (en) Method for producing indole-3-carboxylic acid derivative
JP2001292790A (en) Method for producing novel 4-halogenated-3-hydroxybutyrate
Bassanini Biocatalytic Strategies for Selective Organic Synthesis
JPH10295391A (en) Method for producing (S) -1- (3-trifluoromethylphenyl) ethanol
JPH0884597A (en) Method for producing optically active glycidol
JP2001039941A (en) Novel optically active 4-amino-2-methylbutyric acid derivative and method for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999964770

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2354554

Country of ref document: CA

Ref country code: CA

Ref document number: 2354554

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09857579

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999964770

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999964770

Country of ref document: EP